Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 620, pseudogene (RNU6-620P) is classified as a pseudogene of U6 small nuclear RNA (U6 snRNA). U6 snRNA is a non-coding RNA component integral to the spliceosome, involved in the removal of introns from pre-messenger RNA through splicing[1][3]. However, pseudogenes such as RNU6-620P generally lack the ability to code for functional RNA or protein products due to accumulated mutations or the lack of necessary regulatory elements[2]. There is no evidence that RNU6-620P has a direct biological function, disease association, or pharmacological relevance, and it is not recognized as a therapeutic target. It is considered a product of genomic duplication or retrotransposition, serving primarily as a genomic fossil without recognized function[2]. This entry does not describe a true therapeutic target such as a receptor, enzyme, or transporter. As a pseudogene, it lacks druggability, functional relevance in cell signaling, or direct disease roles based on current scientific knowledge. Therefore, it should not be treated as a valid molecular therapeutic target[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 620, pseudogene (RNU6-620P).